Lv7
4620 积分 2022-12-02 加入
Iptacopan in IgA Nephropathy — Final 24-Month Data
12小时前
已完结
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
12小时前
已完结
Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy
12小时前
待确认
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
1天前
已完结
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
13天前
已完结
Novel Grb14-Mediated Cross Talk between Insulin and p62/Nrf2 Pathways Regulates Liver Lipogenesis and Selective Insulin Resistance
15天前
已完结
Novel Grb14-Mediated Cross Talk between Insulin and p62/Nrf2 Pathways Regulates Liver Lipogenesis and Selective Insulin Resistance
15天前
已关闭
Novel Grb14-Mediated Cross Talk between Insulin and p62/Nrf2 Pathways Regulates Liver Lipogenesis and Selective Insulin Resistance
15天前
已关闭
Effects of Gastric Acid Suppression, Cytochrome P4503A Inhibition and Induction, and Food on the Pharmacokinetics of Tinlarebant in Healthy Adults
25天前
已完结
RNAi-based drug design: considerations and future directions
1个月前
已完结
皖公网安备34019202002308
